Ana Guerrero

Ana Guerrero

Auto-generated profile, based on publicly available information

Ana Guerrero

MRC London Institute of Medical Sciences (LMS), London, UK

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 October 2019 in Nature Metabolism
Verified
Journal Article
Closed access
PDF file
AGAna Guerrero
Ana Guerrero
NHNicolás Herranz
Nicolás Herranz
BSBin Sun
Bin Sun
VWVerena Wagner
Verena Wagner
SGSuchira Gallage
Suchira Gallage
JGJesús Gil
Jesús Gil

1 September 2021 in Trends in Neurosciences
Verified
Journal Article
Closed access
AGAna Guerrero
Ana Guerrero
BSBart De Strooper
Bart De Strooper
IAI. Lorena Arancibia-Cárcamo
I. Lorena Arancibia-Cárcamo

16 March 2020 in Aging Cell
Verified
Journal Article
Open access
PDF file
AGAna Guerrero
Ana Guerrero
RGRomain Guiho
Romain Guiho
NHNicolás Herranz
Nicolás Herranz
AUAnthony Uren
Anthony Uren
DWDominic J. Withers
Dominic J. Withers
JGJesús Gil
Jesús Gil
Senescence is a stable growth arrest that impairs the replication of damaged, old or preneoplastic cells, therefore contributing to tissue homeostasis. Senescent cells accumulate during ageing and are associated with cancer, fibrosis and many age‐related pathologies. Recent evidence suggests that the selective elimination of senescent cells can be effective on the treatment of many of these senescence‐associated diseases. A universal characteristic of senescent cells is that they display elevated activity of the lysosomal β‐galactosidase, and this has been exploited as a marker for senescence (senescence‐associated β‐galactosidase activity). Consequently, we hypothesized that galactose‐modified cytotoxic prodrugs will be preferentially processed by senescent cells, resulting in their selective killing. Here, we show that different galactose‐modified duocarmycin (GMD) derivatives preferentially kill senescent cells. GMD prodrugs induce selective apoptosis of senescent cells in a lysosomal β‐galactosidase (GLB1)‐dependent manner. GMD prodrugs can eliminate a broad range of senescent cells in culture, and treatment with a GMD prodrug enhances the elimination of bystander senescent cells that accumulate upon whole‐body irradiation treatment of mice. Moreover, taking advantage of a mouse model of adamantinomatous craniopharyngioma (ACP), we show that treatment with a GMD prodrug selectively reduced the number of β‐catenin‐positive preneoplastic senescent cells. In summary, the above results make a case for testing the potential of galactose‐modified duocarmycin prodrugs to treat senescence‐related pathologies.

28 November 2017 in Nature Communications
Verified
Journal Article
Open access
PDF file
Jose Mario Gonzalez-MeljemJose Mario Gonzalez-Meljem
Jose Mario Gonzalez-Meljem
SHScott Haston
Scott Haston
GCGabriela Carreno
Gabriela Carreno
JAJohn R. Apps
John R. Apps
SPSara Pozzi
Sara Pozzi
JMJuan Pedro Martinez-Barbera
Juan Pedro Martinez-Barbera
Senescent cells may promote tumour progression through the activation of a senescence-associated secretory phenotype (SASP), whether these cells are capable of initiating tumourigenesis in vivo is not known. Expression of oncogenic β-catenin in Sox2+ young adult pituitary stem cells leads to formation of clusters of stem cells and induction of tumours resembling human adamantinomatous craniopharyngioma (ACP), derived from Sox2− cells in a paracrine manner. Here, we uncover the mechanisms underlying this paracrine tumourigenesis. We show that expression of oncogenic β-catenin in Hesx1+ embryonic precursors also results in stem cell clusters and paracrine tumours. We reveal that human and mouse clusters are analogous and share a common signature of senescence and SASP. Finally, we show that mice with reduced senescence and SASP responses exhibit decreased tumour-inducing potential. Together, we provide evidence that senescence and a stem cell-associated SASP drive cell transformation and tumour initiation in vivo in an age-dependent fashion.

1 December 2011 in Experimental Cell Research
Verified
Journal Article
Closed access
GHGonzalo Hernández
Gonzalo Hernández
Hind LalHind Lal
Hind Lal
Miguel FidalgoMiguel Fidalgo
Miguel Fidalgo
AGAna Guerrero
Ana Guerrero
JZJuan Zalvide
Juan Zalvide
CPCelia M Pombo
Celia M Pombo

1 March 2012 in Journal of Biological Chemistry
Verified
Journal Article
Open access
Miguel FidalgoMiguel Fidalgo
Miguel Fidalgo
AGAna Guerrero
Ana Guerrero
MFMaría Fraile
María Fraile
CICristina Iglesias
Cristina Iglesias
CPCelia M. Pombo
Celia M. Pombo
JZJuan Zalvide
Juan Zalvide
While studying the functions of CCM3/PDCD10, a gene encoding an adaptor protein whose mutation results in vascular malformations, we have found that it is involved in a novel response to oxidative stress that results in phosphorylation and activation of the ezrin/radixin/moesin (ERM) family of proteins. This phosphorylation protects cells from accidental cell death induced by oxidative stress. We also present evidence that ERM phosphorylation is performed by the GCKIII kinase Mst4, which is activated and relocated to the cell periphery after oxidative stress. The cellular levels of Mst4 and its activation after oxidative stress depend on the presence of CCM3, as absence of the latter impairs the phosphorylation of ERM proteins and enhances death of cells exposed to reactive oxygen species. These findings shed new light on the response of cells to oxidative stress and identify an important pathophysiological situation in which ERM proteins and their phosphorylation play a significant role.